Eli Lilly expects to miss its recent revenue estimate for 2024 by about $400 million, according to a preliminary report.
Private investment firm Bridgewest is combing its Australia-based biologics CDMO BioCina and its sterile injectable ...
Nippon Shinyaku pays $110M upfront to Regenxbio for US/Asia rights to RGX-121 and RGX-111 gene therapies for ...
The top three pharmacy benefit managers hiked the prices of dozens of 'specialty' generic drugs, some by more than 1000% of ...
Daiichi Sankyo is spending $132.5 million to buy an antibody outright that it had already licensed from Glycotope.
IgA1 reduction in 4 hours, outperforming Vertex's povetacicept and Otsuka's sibeprenlimab. Plans for Phase 3 in IgAN.
XO Health launches health plan in 4 cities, offering employers alternative coverage with fixed-price care packages and ...
Four Lykos Therapeutics board members have stepped down and another departed last month, the aftermath of a stalemate over how to finance the psychedelic company's clinical future.
For as long as I’ve been a healthcare reporter, the JP Morgan Healthcare Conference has served as a newsy way … Get ...
Former FDA Commissioner Scott Gottlieb said Robert F. Kennedy Jr. should not lead the US health agencies, underscoring the ...
Is the frenzy of JPM dealmaking finally underway? GSK announced Monday morning that it will acquire the privately-held ...
The US Court of Appeals for the Federal Circuit on Friday found a key patent of Novartis' Entresto valid, reversing a lower ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback